Oncotarget recently published "Comparison of the prognostic value of immunoinflammation-based biomarkers in patients with gastric cancer" which reported that in this study, the authors clarified the prognostic impact of immuno inflammation-based indices, i. e. SII, neutrophil/lymphocyte ratio, and platelet/lymphocyte ratio, in gastric cancer patients.
In multivariate analysis, the American Society of Anesthesiologists physical status, tumor differentiation, pathological Tumor, Node, Metastasis stage, and carcinoembryonic antigen were independent prognostic factors for OS in all patients.
Further, multivariate analysis revealed that age, ASA-PS, tumor differentiation, and pTNM stage were independent prognostic factors for OS among patients without inflammation; SII was not a prognostic factor for OS.
Meanwhile, body mass index, ASA-PS, and SII were independent prognostic factors for OS among patients with inflammation.
The prognostic value of SII was compared between a low SII group
Dr. Noriyuki Hirahara from The Shimane University Faculty of Medicine said, "Numerous studies have reported that cancer-related inflammation is an indispensable component of the tumor microenvironment."
Cancer causes local or systemic inflammation, ultimately promoting cancer initiation and progression by escaping from the immune system.
Additionally, systemic immunoinflammation has been generally accepted to affect the cancer microenvironment in a way that favors proliferation, invasion, and migration of cancer cells, while reducing the response to anticancer agents.
Several systemic immunoinflammatory parameters have been evaluated as candidates for predicting long-term survival in various malignancies because systemic immunoinflammation is considered as a consequence, rather than the cause of cancer.
Currently, prognostic prediction in cancer patients mainly depends on the Tumor, Node, Metastasis staging system, but the final TNM stage is defined by the histological evaluation of resected specimens after surgery.
Preoperative prognostic prediction remains difficult, and the definitive predictor of survival in cancer patients is a subject of ongoing debate.
The Hirahara Research Team concluded in their Oncotarget Research Paper, "this study showed that preoperative SII is the most significant prognostic biomarker for OS, especially in patients with gastric cancer with inflammation, when compared to two-factor markers such as NLR and PLR. In the future, properly designed prospective studies should confirm the more significant prognostic value of SII in gastric cancer."
In the future, properly designed prospective studies should confirm the more significant prognostic value of SII in gastric cancer
DOI - https://doi.org/10.18632/oncotarget.27653
Full text - https://www.oncotarget.com/article/27653/text/
Correspondence to - Noriyuki Hirahara - norinorihirahara@yahoo.co.jp
Keywords - gastric cancer, systemic immune-inflammation index, CRP, overall survival
About Oncotarget
Oncotarget is a biweekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:
SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls
Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957x105
Copyright © 2024 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC